Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)

NCT02412306 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02412306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02412306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
June 4, 2015
Completion date
July 4, 2019
Enrollment
66 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed refractory b precursor acute lymphoblastic leukemia